The first and only
sublingual tablet

for the treatment of nocturia due to
nocturnal polyuria (NP) in adults who awaken at least 2 times per night to void1

NOCDURNA dissolves rapidly and starts working quickly1

Sublingual tablet dissolves
in seconds—without water1

NOCDURNA starts working in minutes

Onset of antidiuretic action occurs within 30 minutes1

ELIMINATION STARTS QUICKLY

2.8 hours

Elimination from the body starts quickly—a half-life of 2.8 hours1

Patients taking NOCDURNA wake up fewer times to void

The majority of patients had their nightly voids cut by 1/31*

78% Women

95% CI [1.36, 3.41] (N=118)

67% Men

95% CI [1.30, 3.14] (N=102)

In a study where nocturia patients averaged 3 nighttime bathroom visits1

NOCDURNA reduced nighttime voids by nearly half1

52%

IN WOMEN†

95% CI [-0.5, -0.1] (N=118)

43%

IN MEN†

95% CI [-0.6, -0.2] (N=102)

  1. Mean adjusted probability of achieving at least a 33% reduction from baseline in average number of nightly voids. 33% responder rate used to ensure a reasonable estimate of clinical benefit.
  2. Reduction of 1.5 voids in women and 1.3 voids in men relative from mean baselines of 2.9 in women and 3.0 in men.

NOCDURNA reduced and sometimes eliminated nighttime voids

Percent (%) of nights with only 1 void1

Percent (%) of men and women with no voids1

NOCDURNA offers specific doses for men: 55.3 mcg per day

Men taking NOCDURNA
doubled their nights
with no voids vs placebo

95% CI [4%, 14%] (N=102)

NOCDURNA offers specific doses for women: 27.7 mcg per day

Women taking NOCDURNA
increased their nights without
voids by 19% over baseline‡

95% CI [-3%, 11%] (N=118)

  1. Nights without voids measured 0% at baseline and increased to 19% at the end of 3 months.

Patients taking OAB or BPH medications were also included in the clinical trials1

Antimuscarinics, α-blockers, and α-reductase inhibitors were taken concomitantly
for mild OAB or BPH1

Study Description

The efficacy of NOCDURNA was established in two 3-month, randomized, double-blind, placebo-controlled, multi-center trials in adults over 18 years of age. Study 1 included 237 female patients and Study 2 included 230 male patients. Women received NOCDURNA 27.7 mcg and men received NOCDURNA 55.3 mcg. The co-primary endpoints were the change in number of nighttime voids compared to baseline and the percentage of patients who achieved a 33% reduction from baseline in the mean number of nighttime voids.1

Reference: 1. NOCDURNA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.